Hikma signs agreement with EffRx for licensing of osteoporosis treatment Binesto
4th Feb 2013 10:37
FTSE 250-listed pharmaceuticals group Hikma Pharmaceuticals has signed an agreement with EffRx for the licensing and distribution of osteoporosis treatment Binosto. The treatment, which is to be distributed throughout the Middle East and North Africa (MENA), represents the only buffered solution f
Read moreTuesday broker round-up UPDATE
15th Jan 2013 07:17
African Barrick Gold: Investec lowers its target price from 526p to 405p, while upgrading from hold to buy. ARM Holdings: Morgan Stanley raises its target price from 725p to 911p, while downgrading to equal-weight. Investec ups target price from 800p to 900p and downgrades from buy to hold. Aurum
Read moreThursday tips round-up: Sainsbury's, Aviva, Hikma Pharmaceuticals
10th Jan 2013 07:10
Sainsbury's update yesterday revealed that Christmas same-store sales rose at the lowest rate seen in eight years. However, Questor thinks there was a lot to be optimistic about in the announcement. The company's like-for-like sales met expectations and its higher-margin (but cheaper) own-label good
Read moreHikma boosts Egyptian growth with acquisition
9th Jan 2013 07:59
FTSE 250 pharmaceutical group HIkma is to buy the Egyptian Company for Pharmaceuticals & Chemical Industries as it strengthens its position in a rapidly growing market. It is to pay EGP142.4m - around $22.2m - to buy the firm from a consortium of shareholders. Hikma's Chief Executive, Said Darwaz
Read moreHikma Pharmaceuticals announces launch of argatroban injection
13th Dec 2012 09:49
Hikma Pharmaceuticals announced Thursday the US launch of an injection for the treatment of thrombosis in adults. The FSTE 250 multinational group is releasing the argatroban injection after receiving approval from the US Food and Drug Administration earlier this year. The London-based pharmace
Read moreLondon close: Markets in bullish mood ahead of US election results
6th Nov 2012 16:44
- Markets gear up for climax of presidential race - Economic data disappoints - Corporate earnings impress, Resolution leads risers after upgrade The UK stock market shrugged off some disappointing economic data to finish Tuesday's session with decent gains as a barrage of updates and results from
Read moreFTSE 250 movers: Hikma rises on Panmure upgrade
6th Nov 2012 15:30
Hikma Pharmaceuticals got a boost after Panmure Gordon upgraded the stock from hold to buy and lifted its price target from 720p to 825p. Jefferies kept its buy rating on the stock and retained a 890p target. Recycled packing firm DS Smith said it continue to expect substantial year-on-year EPS gr
Read moreTuesday broker round-up
6th Nov 2012 09:03
AB Foods: Jefferies keeps hold rating and 1,365p target; Panmure Gordon ups target from 1,300p to 1,450p, hold rating kept; Investec keeps hold rating and 1,300p target. Aviva: Panmure Gordon maintains buy rating and 425p target. Babcock: Jefferies keeps buy rating and 970p target; Seymour Pierce
Read moreLondon close: Footsie struggles to hold on to gains after jobs data
2nd Nov 2012 16:42
- US jobs provide temporary boost, but gains trimmed - Data unlikely to change Fed's stance, says analyst - Financials Admiral and RBS disappoint While the closely-watched US jobs report provided a bit of a bounce in early afternoon trade, the Footsie had pared gains to finish flat by the close as
Read moreFTSE 250 movers: Shares in Bumi rocket on proposal news
2nd Nov 2012 16:23
Mining group Bumi advanced after saying it has appointed Rothschild Goup as its financial adviser with immediate effect to evaluate the proposal received from Long Haul Holdings. Shares in Dixons rose once again, boosted by the news that its main High Street rival, Comet, is likely to go into admi
Read moreLondon midday: Markets cautious ahead of US non-farm payrolls
2nd Nov 2012 11:30
- All eyes on US jobs data - Outcome could be a major factor in presidential elections - Admiral, Meggitt and RBS disappoint The FTSE 100 was little changed by Friday lunchtime, having trade within a narrow range for most of the morning session, with investors nervous ahead the pivotal employment
Read moreHikma to suspend production in New Jersey
2nd Nov 2012 07:29
Hikma Pharmaceuticals is considering the future of its Generics business as its Eatontown facility in New Jersey continues to be dogged by compliance issues. The group has opted to halt commercial production of generic drugs at Eatontown facility in the US until mid-January while it gets to grips
Read moreWednesday broker round-up
24th Oct 2012 09:25
African Barrick Gold: Investec raises target from 485p to 530p, hold rating kept. Aggreko: Seymour Pierce maintains buy rating and 2,500p target. AstraZeneca: Panmure Gordon keeps hold rating and 3,000p target. British American Tobacco: Jefferies keeps buy rating and 3,730p target; Panmure Gordon
Read moreBroker tips: RBS, Weir, Aggreko...
22nd Oct 2012 12:45
Shares in part-nationalised lender Royal Bank of Scotland (RBS) are trading at 0.6 times tangible net asset value (tNAV) and close to a new 17-month high, which has prompted broker Investec to downgrade its rating for the stock from 'hold' to 'sell'. Investec forecasts another "jaw-dropping statuto
Read moreBroker snap: UBS downgrades Hikma to 'sell'
22nd Oct 2012 12:43
UBS has cut its recommendation for pharmaceuticals group Hikma from 'neutral' to 'sell', saying that the market is pricing in a 'blue sky scenario'. The broker said that it is hard to justify Hikma's valuation "as we believe that the market is pricing a blue sky scenario with the US Injectables sup
Read more